• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. 
    •   QMRO Home
    • Wolfson Institute of Preventive Medicine
    • Centre for Cancer Prevention
    • Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.
    •   QMRO Home
    • Wolfson Institute of Preventive Medicine
    • Centre for Cancer Prevention
    • Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.

    View/Open
    Published version (803.7Kb)
    Volume
    9
    Pagination
    595 - ?
    DOI
    10.3332/ecancer.2015.595
    Journal
    Ecancermedicalscience
    ISSN
    1754-6605
    Metadata
    Show full item record
    Abstract
    The global cancer burden continues to rise and the war on cancer can only be won if improvements in treatment go hand in hand with therapeutic cancer prevention. Despite the availability of several efficacious agents, utilisation of preventive therapy has been poor due to various barriers, such as the lack of physician and patient awareness, fear of side effects, and licensing and indemnity issues. In this review, we discuss these barriers in detail and propose strategies to overcome them. These strategies include improving physician awareness and countering prejudices by highlighting the important differences between preventive therapy and cancer treatment. The importance of the agent-biomarker-cohort (ABC) paradigm to improve effectiveness of preventive therapy cannot be overemphasised. Future research to improve therapeutic cancer prevention needs to include improvements in the prediction of benefits and harms, and improvements in the safety profile of existing agents by experimentation with dose. We also highlight the role of drug repurposing for providing new agents as well as to address the current imbalance between therapeutic and preventive research. In order to move the field of therapeutic cancer prevention forwards, engagement with policymakers to correct research imbalance as well as to remove practical obstacles to implementation is also urgently needed.
    Authors
    DeCensi, A; Thorat, MA; Bonanni, B; Smith, SG; Cuzick, J
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/11074
    Collections
    • Centre for Cancer Prevention [730]
    Language
    eng
    Licence information
    © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.